Cost-effectiveness analysis of an association of acetylsalicylic acid and sustained-release dipyridamole in the prevention of recurrent stroke in Belgium;Association aas-dypiridamole (asasantine®) dans la prevention des recidives d'avc (analyse cout-efficacite)

Revue Medicale de Liege

Volumn 53, Issue 5, 1998, Pages 265-269

  Kurz, X ^a   Annemans, L ^a   Dresse, A ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acetylsalicylic acid; Cost effectiveness analysis; Dipyridamole; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; PLACEBO; TX 3301;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; SECONDARY PREVENTION; STROKE; SUSTAINED RELEASE PREPARATION; BELGIUM; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; COST; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; DISEASE FREE SURVIVAL; DRUG COMBINATION; ECONOMICS; FOLLOW UP; PHARMACOECONOMICS; PROBABILITY; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY;

ASPIRIN; BELGIUM; CEREBROVASCULAR DISORDERS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FOLLOW-UP STUDIES; HUMANS; MARKOV CHAINS; PLACEBOS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY;

EID: 0032061277     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)